The GLOBO Blog

Clinical trials need to go faster. With an overall success rate of only about 14%, and each trial carrying the weight of potentially hundreds of thousands of dollars each day, pharmaceutical companies’ performance hinges on conducting trials with greater efficiency.

It is no secret that business of healthcare in the US is expensive, inefficient and ripe for disruption. For over a decade, prognosticators have touted the benefits of telemedicine as a key disruptor with visions of a holographic doctor who makes housecalls.